Literature DB >> 28496803

New Stroke Prophylaxis Options in Atrial Fibrillation Patients.

George Thomas1, Bruce B Lerman1.   

Abstract

Atrial Fibrillation (AF) is an epidemic that is increasing in size and scope. AF can have many symptoms and cause a variety of negative health impacts.The most important health risk of AF is the increased risk of stroke and systemic thromboembolism.Oral anticoagulation with warfarin has been the gold standard for stroke risk reduction in AF, but new drugs and treatment strategies for AF are changing clinical practice. These new advances could offer better tailoring of treatments to patients with high risk of stroke while reducing the potential bleeding complications.

Entities:  

Year:  2013        PMID： 28496803      PMCID： PMC5153098          DOI： 10.4022/jafib.462

Source DB:  PubMed          Journal:  J Atr Fibrillation        ISSN： 1941-6911


  47 in total

1.  The risk of thromboembolism and need for oral anticoagulation after successful atrial fibrillation ablation.

Authors:  Sakis Themistoclakis; Andrea Corrado; Francis E Marchlinski; Pierre Jais; Erica Zado; Antonio Rossillo; Luigi Di Biase; Robert A Schweikert; Walid I Saliba; Rodney Horton; Prasant Mohanty; Dimpi Patel; David J Burkhardt; Oussama M Wazni; Aldo Bonso; David J Callans; Michel Haissaguerre; Antonio Raviele; Andrea Natale
Journal:  J Am Coll Cardiol       Date:  2010-02-23       Impact factor: 24.094

2.  Success of surgical left atrial appendage closure: assessment by transesophageal echocardiography.

Authors:  Anne S Kanderian; A Marc Gillinov; Gosta B Pettersson; Eugene Blackstone; Allan L Klein
Journal:  J Am Coll Cardiol       Date:  2008-09-09       Impact factor: 24.094

3.  Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence.

Authors:  Yoko Miyasaka; Marion E Barnes; Bernard J Gersh; Stephen S Cha; Kent R Bailey; Walter P Abhayaratna; James B Seward; Teresa S M Tsang
Journal:  Circulation       Date:  2006-07-03       Impact factor: 29.690

4.  Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis.

Authors:  Carl van Walraven; Robert G Hart; Daniel E Singer; Andreas Laupacis; Stuart Connolly; Palle Petersen; Peter J Koudstaal; Yuchiao Chang; Beppie Hellemons
Journal:  JAMA       Date:  2002-11-20       Impact factor: 56.272

5.  Effect of home testing of international normalized ratio on clinical events.

Authors:  David B Matchar; Alan Jacobson; Rowena Dolor; Robert Edson; Lauren Uyeda; Ciaran S Phibbs; Julia E Vertrees; Mei-Chiung Shih; Mark Holodniy; Philip Lavori
Journal:  N Engl J Med       Date:  2010-10-21       Impact factor: 91.245

6.  Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial.

Authors:  Hiroshi Sato; Kinji Ishikawa; Akira Kitabatake; Satoshi Ogawa; Yukio Maruyama; Yoshiyuki Yokota; Takaya Fukuyama; Yoshinori Doi; Seibu Mochizuki; Tohru Izumi; Noboru Takekoshi; Kiyoshi Yoshida; Katsuhiko Hiramori; Hideki Origasa; Shinichiro Uchiyama; Masayasu Matsumoto; Takenori Yamaguchi; Masatsugu Hori
Journal:  Stroke       Date:  2005-12-29       Impact factor: 7.914

7.  Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score=1.

Authors:  Laurent Gorin; Laurent Fauchier; Emilie Nonin; Axel de Labriolle; Ken Haguenoer; Pierre Cosnay; Dominique Babuty; Bernard Charbonnier
Journal:  Thromb Haemost       Date:  2010-02-02       Impact factor: 5.249

8.  Percutaneous left atrial appendage occlusion for patients in atrial fibrillation suboptimal for warfarin therapy: 5-year results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) Study.

Authors:  Peter C Block; Steven Burstein; Paul N Casale; Paul H Kramer; Paul Teirstein; David O Williams; Mark Reisman
Journal:  JACC Cardiovasc Interv       Date:  2009-07       Impact factor: 11.195

9.  Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control.

Authors:  Christopher Ll Morgan; Phil McEwan; Andrzej Tukiendorf; Paul A Robinson; Andreas Clemens; Jonathan M Plumb
Journal:  Thromb Res       Date:  2008-12-04       Impact factor: 3.944

10.  Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W).

Authors:  Jeff S Healey; Robert G Hart; Janice Pogue; Marc A Pfeffer; Stefan H Hohnloser; Raffaele De Caterina; Greg Flaker; Salim Yusuf; Stuart J Connolly
Journal:  Stroke       Date:  2008-03-06       Impact factor: 7.914
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.